Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/408
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | MOLENBERGHS, Geert | - |
dc.contributor.author | BUYSE, Marc | - |
dc.contributor.author | GEYS, Helena | - |
dc.contributor.author | RENARD, Didier | - |
dc.contributor.author | BURZYKOWSKI, Tomasz | - |
dc.contributor.author | ALONSO ABAD, Ariel | - |
dc.date.accessioned | 2004-10-29T08:59:01Z | - |
dc.date.available | 2004-10-29T08:59:01Z | - |
dc.date.issued | 2002 | - |
dc.identifier.citation | Controlled Clinical Trials, 23(6), PII S0197-2456(02)00236-2. p. 607-625 | - |
dc.identifier.issn | 0197-2456 | - |
dc.identifier.uri | http://hdl.handle.net/1942/408 | - |
dc.description.abstract | The validation of surrogate endpoints has been studied by Prentice, who presented a definition as well as a set of criteria that are equivalent if the surrogate and true endpoints are binary. Freedman et al. supplemented these criteria with the so-called proportion explained. Buyse and Molenberghs proposed to replace the proportion explained by two quantities: (1) the relative effect, linking the effect of treatment on both endpoints, and (2) the adjusted association, an individual-level measure of agreement between both endpoints. In a multiunit setting, these quantities can be generalized to a trial-level measure of surrogacy and an individual-level measure of surrogacy. In this paper, we argue that such a multiunit approach should be adopted because it overcomes difficulties that necessarily surround validation efforts based on a single trial. These difficulties are highlighted. | - |
dc.description.sponsorship | Dr. Geys is supported by a grant from IWT — Vlaanderen. Drs. Burzykowski and Alonso are supported by an LUC Bijzonder Onderzoeksfonds grant. | - |
dc.language.iso | en | - |
dc.rights | (C) 2002 Elsevier Science Inc. All rights reserved. | - |
dc.subject | Clinical trials | - |
dc.subject | Clustered data | - |
dc.subject | Surrogate Markers | - |
dc.subject.other | adjusted association; meta-analysis; proportion explained; random-effects model; relative effect; surrogate endpoint; validation | - |
dc.title | Statistical challenges in the evaluation of surrogate endpoints in randomized trials | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 625 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 607 | - |
dc.identifier.volume | 23 | - |
local.bibliographicCitation.jcat | A1 | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
local.bibliographicCitation.artnr | PII S0197-2456(02)00236-2 | - |
dc.identifier.doi | 10.1016/S0197-2456(02)00236-2 | - |
dc.identifier.isi | 000179835100001 | - |
dc.identifier.url | https://www.academia.edu/8393370/Statistical_challenges_in_the_evaluation_of_surrogate_endpoints_in_randomized_trials | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.fullcitation | MOLENBERGHS, Geert; BUYSE, Marc; GEYS, Helena; RENARD, Didier; BURZYKOWSKI, Tomasz & ALONSO ABAD, Ariel (2002) Statistical challenges in the evaluation of surrogate endpoints in randomized trials. In: Controlled Clinical Trials, 23(6), PII S0197-2456(02)00236-2. p. 607-625. | - |
item.validation | ecoom 2004 | - |
item.contributor | MOLENBERGHS, Geert | - |
item.contributor | BUYSE, Marc | - |
item.contributor | GEYS, Helena | - |
item.contributor | RENARD, Didier | - |
item.contributor | BURZYKOWSKI, Tomasz | - |
item.contributor | ALONSO ABAD, Ariel | - |
crisitem.journal.issn | 0197-2456 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0197245602002362-main.pdf | Published version | 119.35 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
91
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
81
checked on May 8, 2024
Page view(s)
62
checked on Sep 6, 2022
Download(s)
264
checked on Sep 6, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.